PALO ALTO, CA, January 25, 2018 – Science Exchange, the world’s leading and most secure enterprise platform for outsourced research and development (R&D) services, announced a partnership with Rapid Novor Inc to offer its REmAb™ Antibody Protein Sequencing Services to scientists around the world using Science Exchange’s R&D platform.
Rapid Novor, Inc. is a Kitchener-Waterloo (Canada)-based CRO dedicated to the development of antibody protein sequencing technologies. The company’s mission is to advance life science research to better human health with next-generation protein sequencing. With the opening of its own state-of-the-art mass spectrometry lab in 2017, the team has successfully sequenced hundreds of monoclonal antibodies directly from the proteins and helped pharmaceutical companies in their antibody drug discovery.
“Our focus is on the development of antibody protein sequencing technologies, and we are the only team that has both a mass spectrometry lab and proprietary sequencing software platform,” said Mingjie Xie, Co-founder and CEO of Rapid Novor, Inc. “We are uniquely positioned to offer superior protein sequencing services to researchers worldwide. The partnership with Science Exchange will allow us to provide easy-to-access services to enterprise biopharma companies and offer them cutting-edge technologies in a seamless manner.”
“We are thrilled to partner with Rapid Novor Inc to make its REmAb™ Antibody Protein Sequencing Services available to scientists worldwide,” said Elizabeth Iorns, Ph.D., co-founder and CEO of Science Exchange. “By partnering with the leading CROs in different research and technology sectors, we are bringing in the best and brightest service providers to our secure and readily available platform so that the scientists can focus on developing breakthrough discoveries. Having Rapid Novor Inc as part of our supplier portfolios is an example of our commitment to making it easy for researchers to access the world’s leading scientific service providers and most innovative scientific technologies.”
About Rapid Novor, Inc.
Rapid Novor, Inc. is the world’s leader in antibody protein sequencing technology. Specializing in the field of mass spectrometry-based proteomics, the team has developed the technology to directly sequence the antibody proteins without needs to access the cell line. As a University of Waterloo spin-off, the company is building its technology portfolios based on the twenty years of scientific research and inventions from Dr. Bin Ma, co-founder and chief scientist. The company’s REmAb™ antibody protein sequencing service has allowed the accurate sequencing of any given antibody proteins routinely. The company’s WILD™ service is the first commercially available service that can accurately distinguish the isomeric isoleucine and leucine using mass spectrometry. For more information, visit www.rapidnovor.com. Follow the company on Twitter @rapidnovor.